Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Assets Average (2020 - 2025)

Historic Assets Average for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $699.4 million.

  • Relay Therapeutics' Assets Average fell 1784.4% to $699.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $699.4 million, marking a year-over-year decrease of 1784.4%. This contributed to the annual value of $857.6 million for FY2024, which is 1175.43% down from last year.
  • As of Q3 2025, Relay Therapeutics' Assets Average stood at $699.4 million, which was down 1784.4% from $764.1 million recorded in Q2 2025.
  • Over the past 5 years, Relay Therapeutics' Assets Average peaked at $1.1 billion during Q4 2022, and registered a low of $693.0 million during Q3 2021.
  • Moreover, its 5-year median value for Assets Average was $851.3 million (2024), whereas its average is $879.1 million.
  • In the last 5 years, Relay Therapeutics' Assets Average skyrocketed by 4849.32% in 2022 and then crashed by 2281.47% in 2023.
  • Quarter analysis of 5 years shows Relay Therapeutics' Assets Average stood at $840.0 million in 2021, then surged by 35.02% to $1.1 billion in 2022, then fell by 22.81% to $875.5 million in 2023, then increased by 2.88% to $900.7 million in 2024, then decreased by 22.35% to $699.4 million in 2025.
  • Its Assets Average was $699.4 million in Q3 2025, compared to $764.1 million in Q2 2025 and $835.3 million in Q1 2025.